Alico Pharmaceuticals completes expansion of production lines at Jincheon Plant < Pharmaceutical Industry < Pharmaceuticals and Distribution < Main article

[의학신문·일간보사=김정일 기자] Alico Pharmaceuticals (CEO Lee Hang-gu), a pharmaceutical-based healthcare specialized company, completed the expansion of the Jincheon factory production line, which is a GMP facility, and held a completion ceremony on the 25th with about 100 people attending, including major partners and business officials.

On this day, Lee Hang-gu, CEO of Alico Pharmaceuticals, said in a welcome speech, “Today’s place will be an inflection point for Alico Pharmaceuticals, which has grown into a mid-sized company, to become a true pharmaceutical company.” I will do everything,” he said.

Since March of last year, Alico Pharmaceuticals has started to expand the production capacity of the GMP plant located in Gwanghyewon, Jincheon-gun, Chungcheongbuk-do.

At the end of last year, the quality control building was completed first, and this time, a solid dosage form manufacturing line equipped with an automated system and some large-capacity facilities were additionally installed and normal operation started.

The quality control building, which was completed last year, is a facility on the 4th floor for welfare promotion, such as expansion of QC/QA and management department facilities and improvement of the working environment of employees according to the expansion of Alico Pharmaceuticals. There is a cafeteria for

In addition, the new manufacturing line will have a production capacity of 1 billion tablets, twice the existing capacity of 500 million tablets, when it is operated normally as a large-capacity automated facility.

Alico Pharmaceuticals plans to reduce the manufacturing cost of mass-produced items through the large-capacity automated line established this time, and increase sales and operating profit through diversification of production, such as small-scale production of various types of existing lines.

Meanwhile, Alico Pharmaceuticals has conducted 26 bioequivalence experiments for in-house conversion of top-selling items such as brain diseases, high blood pressure, and diabetes to strengthen prescription drug sales and market competitiveness from 2021, and will produce them sequentially from this year.